UPDATE: BioCryst Pharmaceuticals Posts Narrower-Than-Expected Q4 Loss

BioCryst Pharmaceuticals Inc. BCRX reported a narrower-than-expected loss for the fourth quarter. The Durham, North Carolina-based company posted a quarterly loss of $11.7 million, or $0.16 per share, versus a year-ago net loss of $5.4 million, or $0.09 per share. Its revenue declined 49.1% to $5.4 million. However, analysts were estimating a loss of $0.21 per share on revenue of $3.64 million. Research and Development expenses rose to $18.5 million from $15.5 million, while general and administrative expenses gained to $2.0 million from $1.4 million. At December 31, 2014, the company had cash, cash equivalents and investments of $114.0 million, compared to $40.8 million at December 31, 2013. For 2015, BioCryst projects net operating cash use of $65 million to $80 million and operating expenses of $75 million to $95 million. "We are proud of our 2014 achievements; most notably our successful completion of the BCX4161 OPuS-1 trial and the initiation of OPuS-2 for the treatment of hereditary angioedema, as well as our first U.S. regulatory approval of a BioCryst discovered drug, RAPIVABTM for the treatment of acute uncomplicated influenza in patients 18 years and older," said Jon P. Stonehouse, President & Chief Executive Officer. BioCryst Pharmaceuticals shares gained 1.68% to $10.30 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsloss
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!